Evolus (NASDAQ:EOLS) posted its earnings results on Tuesday. The company reported ($0.47) earnings per share for the quarter, topping the consensus estimate of ($0.85) by $0.38, Fidelity Earnings reports. The business had revenue of $19.45 million during the quarter, compared to analysts’ expectations of $18.93 million.
Evolus stock traded up $0.06 during mid-day trading on Friday, hitting $8.59. 731,094 shares of the company traded hands, compared to its average volume of 738,105. Evolus has a one year low of $8.28 and a one year high of $29.50. The stock has a market cap of $289.74 million, a price-to-earnings ratio of -2.67 and a beta of 4.30. The company has a debt-to-equity ratio of 4.53, a quick ratio of 3.28 and a current ratio of 3.66. The stock has a fifty day moving average price of $10.17 and a 200-day moving average price of $13.53.
EOLS has been the subject of several recent analyst reports. Mizuho reaffirmed a “buy” rating and set a $20.00 price objective on shares of Evolus in a research note on Tuesday. Barclays reaffirmed a “sell” rating and set a $9.00 price objective on shares of Evolus in a research note on Thursday. ValuEngine raised shares of Evolus from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 23rd. Leerink Swann initiated coverage on shares of Evolus in a research note on Tuesday, November 26th. They set an “outperform” rating and a $25.00 price objective for the company. Finally, Svb Leerink initiated coverage on shares of Evolus in a research note on Tuesday, November 26th. They set an “outperform” rating and a $25.00 price objective for the company. Two analysts have rated the stock with a sell rating, two have assigned a hold rating, eight have assigned a buy rating and one has given a strong buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and an average target price of $24.55.
In other Evolus news, insider Rui Avelar sold 39,442 shares of Evolus stock in a transaction that occurred on Tuesday, January 7th. The shares were sold at an average price of $10.71, for a total transaction of $422,423.82. Following the completion of the sale, the insider now directly owns 70,802 shares in the company, valued at $758,289.42. The sale was disclosed in a document filed with the SEC, which is available at
the SEC website
. Insiders own 3.90% of the company’s stock.
Evolus Company Profile
Evolus, Inc, a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.
Read More: Portfolio Manager
Receive News & Ratings for Evolus Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Evolus and related companies with MarketBeat.com’s FREE daily email newsletter.
All copyrights for this article are reserved to This Publisher